Stock AnalizMedline Inc. MDLN
Medical/Dental Instruments · IPO 2025 · data as of November 13, 2026
Medline Inc. (MDLN) is a healthcare company listed in the US with a market value of about $51.9B. In the twelve months to September 30, 2026 it had revenue of $30.7B and net income of $566M, a net margin of 1.8%.
Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is future growth (2/5); the weakest is value (0/5).
Key numbers: a P/E of 89.7, a price to free cash flow of 27.4, a 5-year average ROIC of 9%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 48% below the current price.
Score: 1.0 / 5
Checks passed
- Revenue growth above 10% last year
- Profit margin improving
- Positive free cash flow
- Liabilities below 60% of assets
- Stock-based pay below 5% of revenue
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
- Strong R&D investment or growth above 20%
Valuation
Growth and quality
Financials, last 3 years
| Fiscal year | TTM | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Revenue | $30.7B | $28.4B | $25.5B | $23.2B |
| Net income | $566M | $1.2B | $1.2B | $234M |
| Free cash flow | $1.9B | $1.3B | $1.4B | $1.4B |
| EPS (diluted) | $0.64 | $-0.01 | — | — |
| Net margin | 1.8% | 4.1% | 4.6% | 1.0% |
| ROIC | — | 8.6% | — | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 26 analysts is $45.35, 15% above the current price; targets range from $34.00 to $55.00; the consensus rating is “Buy”; expected EPS is $1.56 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Medline’s P/E ratio?
About 89.7, based on the last twelve months of diluted earnings per share (forward P/E about 26.1).
Is Medline stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 48% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Medline pay a dividend?
Not currently.
Is Medline a good stock to buy?
We do not give buy or sell advice. Medline scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.